Xenetic Biosciences
XBIO
8 hedge funds and large institutions have $90.1K invested in Xenetic Biosciences in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.16% less ownership
Funds ownership: 0.32% → 0.16% (-0.16%)
56% less capital invested
Capital invested by funds: $205K → $90.1K (-$115K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$10.1K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.24K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$123K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $54K | -$123K | -11,399 | -66% |
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $24K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $9K | +$10.1K | +940 | New |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $3K | +$3.24K | +300 | New |
|
|
RE
5
RBC Europe
London,
United Kingdom
| $96 | – | – | – |
|
|
6
Wells Fargo
San Francisco,
California
| – | +$11 | +1 | +33% |
|
XBIO Hedge Fund Activity: Q3 2020 in Review
8 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2020, worth a combined $90.1K — down 56% from $205K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $10.1K. The largest seller was Renaissance Technologies, cutting an estimated $123K.
- 8 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2020, up from 6 in Q2 2020.
- Funds reported $90.1K of Xenetic Biosciences stock for Q3 2020, down 56% quarter-over-quarter.
- 2 funds opened new Xenetic Biosciences positions in Q3 2020 and 0 closed out, a net change of +2 holders.
- The largest Xenetic Biosciences buyer in Q3 2020 was UBS Group, an estimated $10.1K added.
- The largest Xenetic Biosciences seller in Q3 2020 was Renaissance Technologies, an estimated $123K sold.
Based on aggregated 13F filings for Q3 2020.